Research Topics
| Elizabeth MillerSummaryAffiliation: Health Protection Agency Country: UK Publications
| Collaborators
|
Detail Information
Publications
Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort studyElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London, UK
Lancet Infect Dis 11:760-8. 2011..We assess the effect of the PCV7 vaccination on VT and NVT disease in England and Wales...
Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccineElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
Vaccine 29:9127-31. 2011..VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period...
Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysisElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, UK
BMJ 346:f794. 2013..To evaluate the risk of narcolepsy in children and adolescents in England targeted for vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine (Pandemrix) from October 2009...
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal diseaseAlessia Melegaro
DONDENA Centre for Research on Social Dynamics, Bocconi University, Via Guglielmo Rontgen, Milan, Italy
BMC Infect Dis 10:90. 2010..However the long term effects of PCV are still unclear, as beneficial direct and herd immunity effects might be countered by serotype replacement...
Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological studyElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, London, UK
Lancet 375:1100-8. 2010....
The epidemiology of subacute sclerosing panencephalitis in England and Wales 1990-2002C Miller
Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
Arch Dis Child 89:1145-8. 2004..To assess the impact of measles/mumps/rubella (MMR) vaccine on the epidemiology of subacute sclerosing panencephalitis (SSPE) in England and Wales...
No evidence of an association between MMR vaccine and gait disturbanceE Miller
Immunisation Division, Public Health Laboratory Service, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
Arch Dis Child 90:292-6. 2005..MMR vaccine has been reported to cause gait disturbance, and this possible association has been claimed to support the MMR-causes-autism theory...
Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United KingdomE Miller
Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London, UK
Am J Epidemiol 165:704-9. 2007..48, 95% confidence interval: 0.88, 2.50) as occurred with Urabe-containing vaccines. This study demonstrates the power of active postmarketing surveillance to identify or exclude events too rare to be detected in prelicensure trials...
Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccineRay Borrow
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
Clin Vaccine Immunol 17:154-9. 2010....
Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional studyStefan Flasche
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS Med 8:e1001017. 2011....
Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United KingdomJo Southern
Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Clin Vaccine Immunol 16:194-9. 2009..This study demonstrates that NeisVac-C and Menjugate generate good immunogenicity after the first dose at 2 months of age when coadministered with PCV7 and Pediacel and merit further investigation in single-dose priming strategies...
Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United KingdomDavid Goldblatt
Immunobiology Unit, UCL Institute of Child Health, London, United Kingdom
Pediatr Infect Dis J 29:401-5. 2010..This study was conducted to establish the immunogenicity of licensed PCV (Prevenar) at a reduced, 2 priming dose schedule (2+1) and to evaluate functional responses in the context of vaccine effectiveness...
Safety and immunogenicity of coadministering a combined meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine with 7-valent pneumococcal conjugate vaccine and measles, mumps, and rubella vaccine at 12 months of ageElizabeth Miller
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Clin Vaccine Immunol 18:367-72. 2011..The United Kingdom infant immunization schedule now recommends that these three vaccines may be offered at one visit at between 12 and 13 months of age...
Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinationsJo Southern
Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, UK
Hum Vaccin 2:237-42. 2006..This single blind study was conducted to address safety concerns regarding coadministration of diphtheria/ tetanus (DT,Td) boosters and meningococcal C conjugate (MCC) vaccines containing diphtheria or tetanus conjugate proteins...
Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and WalesNick Andrews
Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
PLoS ONE 6:e28435. 2011..We estimated the effectiveness of PCV-7 against IPD...
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United KingdomCressida Auckland
Immunisation Department, Centre for Infections, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
J Infect Dis 194:1745-52. 2006..Persistence of antibodies may be a more appropriate correlate of long-term protection for MCC vaccines than the ability to generate a booster response on exposure...
Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunityHelen Campbell
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
Clin Vaccine Immunol 17:840-7. 2010..Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016...
Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011Katja Hoschler
Respiratory Virus Unit, Virus Reference Department, Microbiology Services Colindale, Health Protection Agency, 61 Colindale Ave, London, NW9 5HT, UK
Emerg Infect Dis 18:1894-7. 2012..Population-based seroepidemiology confirms that the third wave of influenza A(H1N1)pdm09 virus circulation was associated with a shift in age groups affected, with the highest rate of infection in young adults...
Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United kingdomHelen Findlow
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
Pediatr Infect Dis J 31:616-22. 2012..Recent data have demonstrated that 2 of the 3 MCC vaccines showed potential for use as a single priming dose in infancy...
Invasive pneumococcal disease among HIV-positive individuals, 2000-2009Zheng Yin
HIVand STI Department, Health Protection Agency, London, UK
AIDS 26:87-94. 2012....
7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?Yoon Hong Choi
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS ONE 6:e26190. 2011..However, recent surveillance data show a more rapid replacement of PCV7 IPD cases by non-PCV7 IPD cases than was seen in the US...
Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimationMarc Baguelin
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS ONE 6:e17074. 2011..The method provides a more accurate and continuous measure of incidence than achieved by comparing prevalence in samples grouped by time period...
Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and WalesCaroline L Trotter
Immunisation Department, Health Protection Agency Centre for Infections, London, UK
Hum Vaccin 2:68-73. 2006..The inclusion of a booster dose is likely to improve the impact of the MCC program and reducing the number of doses in infancy will improve cost-effectiveness and create space in the schedule for the addition of other vaccines...
Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and WalesYoon Hong Choi
Health Protection Services Colindale, Health Protection Agency, London, United Kingdom
PLoS ONE 7:e39927. 2012....
The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in EnglandAlbert Jan van Hoek
Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
J Infect 65:17-24. 2012..Three years of post 7-valent pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd protection effects...
Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adultsJo Southern
Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Ave, Colindale, London, United Kingdom
Clin Diagn Lab Immunol 11:1100-4. 2004..The study shows that MCC-TT is safe and immunogenic in naive and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower...
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and WalesNick J Andrews
Statistics, Modelling and Economics Department, Health Protection Services, Health Protection Agency, London, United Kingdom
Vaccine 30:6802-8. 2012..Based on the VE estimates PPV23 was still considered a cost-effective intervention for the low risk elderly...
Accelerating control of pertussis in England and WalesHelen Campbell
Health Protection Agency, London, UK
Emerg Infect Dis 18:38-47. 2012..e., <3 months of age), teenagers, and adults. Future vaccine program changes may be beneficial, but additional detail is required to inform such decisions...
Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in infJo Southern
Immunisation Department, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
Clin Vaccine Immunol 14:1328-33. 2007..15 microg/ml in about 90% of individuals. A booster dose of Hib vaccine given after the first year of life should provide long-lasting protection...
Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypesAlbert Jan van Hoek
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
PLoS ONE 7:e39150. 2012..We investigated the effect of serotype on clinical presentation, outcome, and quality of life lost from invasive pneumococcal disease (IPD) in the context of the 7, 10, and 13 valent pneumococcal conjugate vaccines (PCV7, PCV10, PCV13)...
Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research DatabaseJulia Stowe
Immunisation Department, Health Protection Agency Centre for Infections, London, UK
Am J Epidemiol 169:382-8. 2009....
Role of PCR in the diagnosis of pertussis infection in infants: 5 years' experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007Norman K Fry
Respiratory and Systemic Infection Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London, UK
J Med Microbiol 58:1023-9. 2009..Real-time PCR is an invaluable tool both for enhanced epidemiological surveillance and for the provision of a rapid diagnosis of pertussis where results can affect patient and contact management...
Post-licensure safety of the meningococcal group C conjugate vaccineNick Andrews
Statistics Unit, Health Protection Agency, Centre for Infections, London, UK
Hum Vaccin 3:59-63. 2007..15 (0.80-1.67). There was evidence of an increased risk of convulsions and idiopathic thrombocytopenic purpura following MMR vaccination as previously documented...
Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policyA J Vyse
PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
Epidemiol Rev 24:125-36. 2002
The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in EnglandAlbert Jan van Hoek
Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, London NW9 5EQ, UK
Vaccine 30:7205-13. 2012....
Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccinesNick J Andrews
Department of Statistics, Modelling and Economics, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, UK
Vaccine 29:7913-9. 2011..Reduction in the interval between doses for earlier protection would be at the cost of reduced immunogenicity. The effect of seasonal vaccine on immunogenicity merits further investigation...
The immunogenicity of a novel A (H1N1) vaccine in HIV-infected childrenIfeanyichukwu O Okike
Vaccine Institute, St George s, University of London, London, United Kingdom
Vaccine 29:6636-40. 2011..There were no published data available regarding the immunogenicity of this vaccine in such children...
Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in EnglandAlan P Johnson
Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London, NW9 5EQ, UK
J Infect 55:394-9. 2007....
No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccineJulia Stowe
Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
Vaccine 27:1422-5. 2009....
Immunoglobulin G deficiency in United kingdom children with invasive pneumococcal diseaseElaine Stanford
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
Pediatr Infect Dis J 30:462-5. 2011....
Meningococcal C conjugate vaccine: the experience in England and WalesHelen Campbell
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
Vaccine 27:B20-9. 2009..The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years...
Epidemiology of invasive and other pneumococcal disease in children in England and Wales 1996-1998E Miller
Immunization Division, Communicable Disease Surveillance Centre, London
Acta Paediatr Suppl 89:11-6. 2000....
Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlersP Richmond
Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, London, United Kingdom
J Infect Dis 183:160-3. 2001..This evidence justified the use of a single dose in a catch-up immunization program for children 1-18 years old...
Sero-epidemiology of mumps in western EuropeA Nardone
PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London, NW9 SEQ, UK
Epidemiol Infect 131:691-701. 2003..Sero-surveillance of mumps is an important component of disease control and its usefulness will be enhanced by the development of an international mumps standard...
A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and DenmarkNick Andrews
Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Vaccine 30:3042-6. 2012..The study therefore shows the potential for vaccine safety collaborations across Europe to detect true associations through use of common protocols and sharing of results or data...
No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in EnglandRichard Pebody
Health Protection Agency Centre for Infections, 61 Colindale Avenue, UK
Vaccine 29:2613-8. 2011..Vaccine effectiveness did not differ significantly by age-group or hospitalisation status. There was no evidence prior vaccination with TIV significantly altered subsequent risk of pandemic influenza H1N1 2009 infection...
Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination eraCaroline Trotter
Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
Vaccine 21:1094-8. 2003..This study provides baseline antibody levels which will facilitate the evaluation of the meningococcal serogroup C conjugate vaccination programme...
A novel method of oral fluid collection to monitor immunity to common viral infectionsM C Morris-Cunnington
Immunisation Division, Communicable Disease Surveillance Centre, Health Protection Agency (formerly Public Health Laboratory Service
Epidemiol Infect 132:35-42. 2004..This approach allowed the successful collection of comprehensive individual risk data, but response rates in adults must be improved if oral fluid surveys are to routinely complement serological surveillance...
Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and WalesBruno Pichon
Respiratory and Systemic Infection Laboratory, Health Protection Agency, London, United Kingdom
J Clin Microbiol 51:820-7. 2013....
Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and WalesShamez N Ladhani
Immunisation Department, Health Protection Agency Colindale, London, UK
Emerg Infect Dis 19:61-8. 2013..4% (58/1,332) but higher for meningitis (11.0%) and children with comorbidities (9.1%). Thus, comorbidities were more prevalent in children with IPD caused by non-PCV13 serotypes and were associated with increased case fatality...
Health and economic impact of the seasonal influenza vaccination programme in EnglandMarc Baguelin
Health Protection Agency, United Kingdom
Vaccine 30:3459-62. 2012..The seasonal influenza vaccination programme in England targets individuals over 65 years old and in clinical risk groups...
Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targetsAnthony Nardone
Centre for Infections, Health Protection Agency, London, England
Bull World Health Organ 86:118-25. 2008..To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets...
Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case seriesNick Andrews
Statistics Modelling and Economics Department, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom
Vaccine 29:7878-82. 2011..05 [95% confidence interval (CI) 0.37 to 2.24]). We found no evidence of an increased risk of GBS in the 6 weeks following pandemic influenza vaccination...
New estimates of herpes simplex virus type 2 seroprevalence in England: 'high' but stable seroprevalence over the last decadeMarianne Morris-Cunnington
Immunisation Division, Communicable Disease Surveillance Centre, London, UK
Sex Transm Dis 31:243-6. 2004..This study aimed to ascertain trends in HSV-2 infection in England between 1991 and 2000...
No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndromeBrent Taylor
General and Adolescent Paediatric Unit, Institute of Child Health, University College London, London, UK
Arch Dis Child 92:887-9. 2007..To investigate whether meningococcal C conjugate vaccine (MCCV) caused relapse in children with steroid-responsive nephrotic syndrome...
Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in EnglandNick Andrews
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, United Kingdom
Clin Diagn Lab Immunol 10:780-6. 2003....
Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40Wendy A Knowles
Enteric, Respiratory and Neurological Virus Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London, United Kingdom
J Med Virol 71:115-23. 2003..There is no serological evidence that SV40 entered the human population during the past 80 years, and the possibility of cross-reaction with BKV or JCV antibody must be considered...
Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adultsDavid Goldblatt
Immunobiology Unit, Institute of Child Health, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London, United Kingdom
J Infect Dis 185:397-400. 2002....
The epidemiology of measles in England and Wales since the 1994 vaccination campaignN Gay
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London
Commun Dis Rep CDR Rev 7:R17-21. 1997..The two dose vaccination programme should maintain the herd immunity of the population and the elimination of endemic measles transmission...
Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunizationD Goldblatt
Institute of Child Health, and Immunisation Division, Communicable Disease Surveillance Centre, London, United Kingdom
J Infect Dis 177:1112-5. 1998..Antibody avidity may help distinguish, in persons with low antibody titers, between those who are primed for memory and those who are not...
Mumps surveillance in England and Wales supports introduction of two dose vaccination scheduleN Gay
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London
Commun Dis Rep CDR Rev 7:R21-6. 1997..A second dose of vaccine, which is now being offered to preschool children, will reduce morbidity and should eventually eliminate mumps if coverage is high enough...
A population-based seroprevalence study of hepatitis A virus using oral fluid in England and WalesM C Morris-Cunnington
Communicable Disease Surveillance Centre, Health Protection Agency, London, UK
Am J Epidemiol 159:786-94. 2004..1% and to 12.1% in unvaccinated individuals. The availability of comprehensive risk factor data allowed the description of two risk profiles related to natural infection and vaccination...
Oral fluid collection by post--a pilot study of two approachesM C Morris
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK
Public Health 116:113-9. 2002..In the other age groups additional reminders could prove a cost-effective way of increasing the response rate further...
Bell's palsy and parenteral inactivated influenza vaccineJulia Stowe
Immunisation Department, Health Protection Agency Centre for Infections, London, UK
Hum Vaccin 2:110-2. 2006..78-1.08). There was also no evidence of an increased risk in any age group or following pneumococcal vaccine. A significant increase was seen on the day of vaccination (day 0) probably due to opportunistic recording of cases...
Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal associationNick Andrews
Statistics Unit, Health Protection Agency, Communicable Disease Surveillance Centre, London, United Kingdom
Pediatrics 114:584-91. 2004..CONCLUSIONS: With the possible exception of tics, there was no evidence that thimerosal exposure via DTP/DT vaccines causes neurodevelopmental disorders...
Impact of the 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in infants younger than 90 days in England and walesShamez N Ladhani
Health Protection Services Colindale, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
Clin Infect Dis 56:633-40. 2013....
Risk of convulsions in children after monovalent H1N1 (2009) and trivalent influenza vaccines: a database studyJulia Stowe
Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom
Vaccine 29:9467-72. 2011..These results neither provide evidence of an increased risk of convulsions following TIV over a 10-year surveillance period nor following a single dose of the ASO3 adjuvanted monovalent H1N1 vaccine in 2009/10...
Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagersJo Southern
Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, Colindale, London, UK
Vaccine 23:3829-35. 2005....
Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United KingdomNick Andrews
Statistics Unit, Health Protection Agency, Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
Vaccine 28:7215-20. 2010..Although there were no other significant differences between vaccines the relative incidence was significantly above one on the day of vaccination for convulsions following DTwP/Hib and for apnoea/collapse following DTaP(5)/Hib/IPV...
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introductionCaroline L Trotter
Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
Lancet 364:365-7. 2004..The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained...
The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and WalesMark Jit
Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 6BT, United Kingdom
Vaccine 29:115-22. 2010..Key sources of uncertainty are the cost of vaccine delivery and the quality of life detriment due to a clinically apparent episode of confirmed influenza. The cost of vaccine purchase itself is relatively low...
Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in EnglandNick Andrews
Statistics Unit, Hepatitis, and Blood Safety Department, Health Protection Agency Centre for Infections, London, England
J Infect Dis 203:32-9. 2011..The use of a squalene-containing (AS03) pandemic vaccine for high-risk groups in England allowed vaccine effectiveness (VE) of such novel oil-in-water adjuvanted vaccine to be evaluated...
Laboratory diagnosis of pertussis infections: the role of PCR and serologyNorman K Fry
Respiratory and Systemic Infection Laboratory and Special Projects Laboratory, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
J Med Microbiol 53:519-25. 2004..Rapid diagnosis of B. pertussis infection particularly in infants by PCR, together with serological assays, can enhance surveillance systems for pertussis in all age groups...
Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal diseaseRay Borrow
Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester M13 9XZ, United Kingdom
Infect Immun 76:5305-9. 2008..This serotype-specific unresponsiveness may reflect immune paralysis due to large pneumococcal polysaccharide antigen loads and/or a potential genetic basis for nonresponse to individual pneumococcal serotypes...
Long-term protection in children with meningococcal C conjugate vaccination: lessons learnedRay Borrow
Vaccine Evaluation Unit, NW Regional HPA Laboratory, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
Expert Rev Vaccines 5:851-7. 2006..The assumption that immune memory was predictive of long-term protection is incorrect, at least after vaccination in infancy. Persistence of antibody and herd immunity may be more relevant for long-term disease control...
Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvacJamie Findlow
Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
Infect Immun 74:4557-65. 2006..These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease...
Meningococcal surrogates of protection--serum bactericidal antibody activityRay Borrow
Meningococcal Reference Unit, Health Protection Agency North West Laboratory, Manchester Royal Infirmary, Manchester M13 9WZ, UK
Vaccine 23:2222-7. 2005..SBA activity as a correlate of protection for evaluating the immune response to meningococcal vaccines is described in this review...
Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancyJamie Findlow
Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Royal Infirmary, Manchester, UK
Clin Infect Dis 51:1127-37. 2010..7-2,4). In this trial, we assessed the immunogenicity of these formulations in infants, who are at greatest risk of contracting MenB disease...
Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccineHelen Findlow
Vaccine Evaluation Unit, Health Protection Agency North West, P O Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
Clin Vaccine Immunol 13:507-10. 2006..Further studies on IgG subclasses following meningococcal polysaccharide and conjugate vaccination are needed...
The changing epidemiological pattern of hepatitis A in England and WalesM C Morris
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London
Epidemiol Infect 128:457-63. 2002..Further population-based surveys collecting more in-depth social and demographic data are needed to confirm the main factors influencing hepatitis A seroprevalence and to explain the regional differences...
Seroprevalence of antibody to varicella zoster virus in England and Wales in children and young adultsA J Vyse
Health Protection Agency Sero Epidemiology Unit, Immunisation Division, Communicable Disease Surveillance Centre, London, UK
Epidemiol Infect 132:1129-34. 2004..This was shown to be a more accurate approach to categorizing data from an epidemiological perspective...
Serum antibody kinetics following nasal or parenteral challenge with meningococcal polysaccharide in healthy adultsH Findlow
Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P O Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
Clin Vaccine Immunol 18:424-9. 2011....
A comparison of hepatitis B seroepidemiology in ten European countriesA Nardone
Centre for Infections, Health Protection Agency, London, UK
Epidemiol Infect 137:961-9. 2009..Regular serological surveys to ascertain HBV status within a population, such as reported here, provide important data to assess the need for and to evaluate universal HBV vaccination programmes...
The seroepidemiology of Bordetella pertussis infection in Western EuropeR G Pebody
Immunisation Department, Health Protection Agency HPA Communicable Disease Surveillance Centre, London, UK
Epidemiol Infect 133:159-71. 2005....
Sero-epidemiology of Bordetella pertussis in England and WalesA Nardone
Immunisation Division, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
Vaccine 22:1314-9. 2004..There is an important incidence of infection in the population, which is greater amongst children than adults, but there is only limited evidence of a correlation with epidemic cycles...
The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European regionA Nardone
Health Protection Agency, Centre for Infections, London, UK
Vaccine 25:7866-72. 2007..There are substantial differences in VZV sero-epidemiology within the European region, which will need to be taken into account in designing national policies regarding VZV vaccination...
Prevalence of human papillomavirus antibodies in young female subjects in EnglandM Jit
Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
Br J Cancer 97:989-91. 2007..7% (95% confidence intervals 9.0-12.3) for human papillomavirus (HPV) 6, 2.7% (1.8-3.6) for HPV 11, 11.9% (10.2-13.6) for HPV 16, 4.7% (3.5-5.8) for HPV 18, and 20.7% (18.6-22.7) for any of the four types...
The burden of Helicobacter pylori infection in England and WalesA J Vyse
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK
Epidemiol Infect 128:411-7. 2002..These data suggest H. pylori infection is becoming less common, is acquired at an early age and is unlikely to be resolved unless suitable antimicrobial treatment is sought...
Severe and unrecognised: pertussis in UK infantsN S Crowcroft
Immunisation Division, HPA Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
Arch Dis Child 88:802-6. 2003..To diagnose pertussis using culture, polymerase chain reaction, and serology, in children admitted to intensive care units (PICUs) and some paediatric wards in London, and in their household contacts to determine the source of infection...
Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005R Borrow
Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom
Vaccine 24:5093-107. 2006
Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st centuryA J Vyse
Health Protection Agency, Centre for Infections, Sero Epidemiology Unit, Immunisation Department, London, UK
Epidemiol Infect 134:1303-12. 2006..Investigations into the efficacy of two doses of a mumps containing vaccine should be a priority during the current epidemic...
The current burden of pneumococcal disease in England and WalesA Melegaro
Modelling and Economics Unit, Centre for Infections, 61 Colindale Avenue, Health Protection Agency, London NW9 5EQ, UK
J Infect 52:37-48. 2006..To evaluate the potential impact of various pneumococcal conjugate vaccination strategies, it is critical to ascertain the pre-vaccination epidemiology and to have a detailed evaluation of the current burden of pneumococcal disease...
The European Sero-Epidemiology Network 2: standardization of assay results for hepatitis B virusG Kafatos
Health Protection Agency Centre for Infections, London, UK
J Viral Hepat 14:260-8. 2007..Standardization is a very important tool that allows for international serological comparisons to assess the current vaccination policies and the progress of HBV control in Europe...
Review of the effect of measles vaccination on the epidemiology of SSPEH Campbell
Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
Int J Epidemiol 36:1334-48. 2007..We conducted a comprehensive review of the impact of measles immunization on the epidemiology of SSPE and examined epidemiological evidence on whether there was any vaccine-associated risk...
Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strainsP Richmond
Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, London NW9 5EQ, United Kingdom
Infect Immun 69:2378-82. 2001..MCC-TT vaccine is highly immunogenic and primes for immunologic memory against OAc+ and OAc- MenC strains in infancy...
Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccineJ Southern
Immunisation Department, Centre for Infections, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK
Vaccine 24:215-9. 2006..These results suggest that a reduced number of doses of MCC-TT would be adequate in infancy if given concomitantly with an acellular pertussis-containing vaccine...
Respiratory syncytial virus infection in infants admitted to paediatric intensive care units in London, and in their familiesN S Crowcroft
Immunisation Department, Health Protection Agency, Centre for Infections, London, NW9 5EQ, UK
Eur J Pediatr 167:395-9. 2008..Young infants are most often infected at the same time as or before their parents and siblings, indicating that the source may be outside the household; vaccinating family members may not prevent RSV infection in infants...
Comparing the immunogenicity of AS03-adjuvanted 2009 pandemic H1N1 vaccine with clinical protection in priority risk groups in EnglandChee Fu Yung
Department of Clinical Epidemiology, Communicable Disease Centre, Tan Tock Seng Hospital, Singapore, Singapore
PLoS ONE 8:e56844. 2013..Current immunogenicity licensing criteria for pandemic influenza vaccine may not correlate with clinical protection in individuals with chronic disease or immunocompromised...
MMR vaccine: review of benefits and risksE Miller
Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK
J Infect 44:1-6. 2002
Serological surveillance of rubella in Europe: European Sero-Epidemiology Network (ESEN2)A Nardone
Health Protection Agency, CDSC, London, UK
Euro Surveill 9:5-7. 2004..A coordinated vaccine policy in Europe is needed and the aim of the European Sero-Epidemiology Network (ESEN2) is to standardise serological surveillance in 22 countries for eight diseases, including rubella...
Idiopathic thrombocytopenic purpura and MMR vaccineE Miller
Immunisation Division, Public Health Laboratory Service Communicable Disease Surveillance Centre, Colindale, London NW9 5EQ, UK
Arch Dis Child 84:227-9. 2001..Children with ITP before MMR had no vaccine associated recurrences...
